Flurpiridaz

Summary

Flurpiridaz (CHEMBL494622) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 3
• Chemistry: 368.8 Da · C18H22ClFN2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL494622
Name	Flurpiridaz
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	24864646
Molecular formula	C18H22ClFN2O3
Molecular weight	368.8
InChIKey	RMXZKEPDYBTFOS-UHFFFAOYSA-N

SMILES: CC(C)(C)N1C(=O)C(=C(C=N1)OCC2=CC=C(C=C2)COCCF)Cl

IUPAC name: 2-tert-butyl-4-chloro-5-[[4-(2-fluoroethoxymethyl)phenyl]methoxy]pyridazin-3-one

Parent form; salt/anhydrous children: CHEMBL494623, CHEMBL2107799

Patent coverage: 24 distinct patent families (106 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01347710	PHASE3	COMPLETED	A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.
NCT01681524	PHASE3	WITHDRAWN	Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI
NCT04594941	PHASE2	COMPLETED	A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing Processes

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).